We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 0OCQ market cap is 306.59M. The company's latest EPS is EUR -0.2214 and P/E is -4.16.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 13.73M | 9.92M | 17.41M | 10.34M | 7.9M |
| Operating Income | -25.34M | -23.99M | -23.52M | -29.9M | -30.01M |
| Net Income | -18.8M | -17.23M | -19.54M | -32.8M | -22.33M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 115.48M | 85.45M | 101.84M | 66.44M | 45.22M |
| Total Liabilities | 49.78M | 35.2M | 34.63M | 28.6M | 29.61M |
| Total Equity | 65.7M | 50.25M | 67.21M | 37.84M | 15.61M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -22.41M | -28.74M | -31.94M | -20.3M | -34.67M |
| Investing | -531k | 17.74M | 16.79M | 20.27M | 34.57M |
| Financing | 22.4M | 14.94M | 15.77M | -1.48M | 11.37M |
| Market Cap | 306.59M |
| Price to Earnings Ratio | -4.16 |
| Price to Sales Ratio | 11.75 |
| Price to Cash Ratio | 5.92 |
| Price to Book Ratio | 5.94 |
| Dividend Yield | - |
| Shares Outstanding | 100.85M |
| Average Volume (1 week) | 5 |
| Average Volume (1 Month) | 3 |
| 52 Week Change | 0.00% |
| 52 Week High | 3.04 |
| 52 Week Low | 3.04 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Transgene Sa |
| Address |
400 boulevard gonthier d’andernach-parc d'innovation illkirch-graffenstaden, bas-rhin 67405 |
| Website | https://www.transgene.fr |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
